Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected around 13 million people and has caused more than 5.7 lakh deaths worldwide since December 2019. In the absence of FDA approved drugs for its treatment, only symptomatic management is done.
Methods: We attempted to uncover potential therapeutic targets of spike, helicase, and RNA dependent RNA polymerase (RdRp) proteins of the SARS-CoV-2 employing a computational approach. The PDB structure of spike and RdRp and predicted structure of helicase proteins were docked with 100 approved anti-viral drugs, natural compounds, and some other chemical compounds.
Results: The anti-SARS ligands EK1 and CID 23631927, and NCGC00029283 are potential entry inhibitors as they showed affinity with immunogenic Receptor Binding Domain (RBD) of the spike protein. This RBD interacts with Angiotensin Converting Enzyme (ACE2) receptor, facilitating the entry of virion in the host cells. The FDA approved drugs, including Nelfinavir, Saquinavir, Tipranavir, Setrobuvir, Indinavir, and Atazanavir, showed potential inhibitory activity against targeted domains and thus, may act as entry or replication inhibitor or both. Furthermore, several anti-HCoV natural compounds, including Amentoflavone, Rutin, and Tannin, are also potential entry and replication inhibitors as they showed affinity with RBD, P-loop containing nucleoside triphosphate hydrolase, and the catalytic domain of the respective protein. Dithymoquinone showed significant inhibitory potential against the fusion peptide of S2 domain. Importantly, Tannin, Dithymoquinone, and Rutin can be extracted from Nigella sativa seeds and thus, may prove to be one of the most potential anti-SARS-CoV-2 inhibitors.
Conclusion: Several potential ligands were identified with already known anti-HCoVs activities. Furthermore, as this study showed that some of the ligands acted as both entry and replication inhibitors against SARS-CoV-2, it is envisaged that a combination of either inhibitor with a dual mode of action would prove to be a much desired therapeutic option against this viral infection.
Keywords: SARS-CoV-2, spike, helicase, RdRp, virtual screening, potential inhibitors, drug repurposing, natural compounds
Coronaviruses
Title:Virtual Screening of Potential Therapeutic Inhibitors Against Spike, Helicase, and Polymerase of SARS-CoV-2 (COVID-19)
Volume: 2 Issue: 1
Author(s): Ayesha Tazeen, Farah Deeba, Aftab Alam, Rafat Ali, Romana Ishrat, Anwar Ahmed, Sher Ali and Shama Parveen*
Affiliation:
- Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi,India
Keywords: SARS-CoV-2, spike, helicase, RdRp, virtual screening, potential inhibitors, drug repurposing, natural compounds
Abstract:
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected around 13 million people and has caused more than 5.7 lakh deaths worldwide since December 2019. In the absence of FDA approved drugs for its treatment, only symptomatic management is done.
Methods: We attempted to uncover potential therapeutic targets of spike, helicase, and RNA dependent RNA polymerase (RdRp) proteins of the SARS-CoV-2 employing a computational approach. The PDB structure of spike and RdRp and predicted structure of helicase proteins were docked with 100 approved anti-viral drugs, natural compounds, and some other chemical compounds.
Results: The anti-SARS ligands EK1 and CID 23631927, and NCGC00029283 are potential entry inhibitors as they showed affinity with immunogenic Receptor Binding Domain (RBD) of the spike protein. This RBD interacts with Angiotensin Converting Enzyme (ACE2) receptor, facilitating the entry of virion in the host cells. The FDA approved drugs, including Nelfinavir, Saquinavir, Tipranavir, Setrobuvir, Indinavir, and Atazanavir, showed potential inhibitory activity against targeted domains and thus, may act as entry or replication inhibitor or both. Furthermore, several anti-HCoV natural compounds, including Amentoflavone, Rutin, and Tannin, are also potential entry and replication inhibitors as they showed affinity with RBD, P-loop containing nucleoside triphosphate hydrolase, and the catalytic domain of the respective protein. Dithymoquinone showed significant inhibitory potential against the fusion peptide of S2 domain. Importantly, Tannin, Dithymoquinone, and Rutin can be extracted from Nigella sativa seeds and thus, may prove to be one of the most potential anti-SARS-CoV-2 inhibitors.
Conclusion: Several potential ligands were identified with already known anti-HCoVs activities. Furthermore, as this study showed that some of the ligands acted as both entry and replication inhibitors against SARS-CoV-2, it is envisaged that a combination of either inhibitor with a dual mode of action would prove to be a much desired therapeutic option against this viral infection.
Export Options
About this article
Cite this article as:
Tazeen Ayesha , Deeba Farah , Alam Aftab, Ali Rafat , Ishrat Romana , Ahmed Anwar , Ali Sher and Parveen Shama *, Virtual Screening of Potential Therapeutic Inhibitors Against Spike, Helicase, and Polymerase of SARS-CoV-2 (COVID-19), Coronaviruses 2021; 2 (1) . https://dx.doi.org/10.2174/2666796701999200826114306
DOI https://dx.doi.org/10.2174/2666796701999200826114306 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Initial Remedial Action to Coronavirus in India: A Study
Current Respiratory Medicine Reviews COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice
Current Hypertension Reviews <i>In-silico</i> Discovery of Fungal Metabolites Bergenin, Quercitrin and Dihydroartemisinin as Potential Inhibitors against Main Protease of SARSCoV- 2
Coronaviruses Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Infective Drug Discovery Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology Discovery of Potential Inhibitors of the Receptor-binding Domain (RBD) of Pandemic Disease-causing SARS-CoV-2 Spike Glycoprotein from Triphala Through Molecular Docking
Current Chinese Chemistry Hydroxychloroquine Induced DRESS (Drug Rash with Eosinophilia and Systemic Symptoms Syndrome) Mimicking SARS-COV-2 Illness: A Case Report with Review
Coronaviruses COVID-19: An Opinion of Prevention and Dietary Based Management Hypothesis
Coronaviruses Diagnostic Value of Chest CT in Coronavirus Disease 2019 (COVID-19)
Current Medical Imaging Design Potential Selective Inhibitors for Treating Cancer by Targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with Core Hopping Approach
Protein & Peptide Letters In Vivo and In Vitro Evaluation of the Therapeutic Potential of Some Turkish Scorzonera Species as Wound Healing Agent
Current Pharmaceutical Design Interaction Between Two Residues in the Inter-Domain Interface of Escherichia coli Peptidase N Modulates Catalytic Activity
Protein & Peptide Letters The Plausible Role of Indian Traditional Medicine in Combating Corona Virus (SARS-CoV 2): A Mini-Review
Current Pharmaceutical Biotechnology Molecular Recognition of Human Angiotensin-Coverting Enzyme I (hACE I) and Different Inhibitors
Current Topics in Medicinal Chemistry The Use of Cyclodextrin or its Complexes as a Potential Treatment Against the 2019 Novel Coronavirus: A Mini-Review
Current Drug Delivery Study of SARS-nCoV2 Indian Isolates Gaining Insights into Mutation Frequencies, Protein Stability and Prospective Effect on Pathogenicity
Coronaviruses Can Cannabinoids Suppress the Cytokines Cascade in Patients with Coronavirus Disease COVID-19? A Mini-Review
Coronaviruses COVID-19 in People with Diabetes: Perspectives from Saudi Arabia
Current Diabetes Reviews COVID-19: A Review on Epidemiology, Clinical Features and Possible Potential Drugs Based on Available Case Studies
Coronaviruses